On the public citation graph
https://doi.org/10.2139/ssrn.3978554
0 signed · 39 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1001/archneur.63.10.1383openalex-extracted
Altered CD4+/CD8+ T-Cell Ratios in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis
inferredcites →https://doi.org/10.1002/(sici)1097-0258(19980430)17:8<873::aid-sim779>3.0.co;2-iopenalex-extracted
Interval estimation for the difference between independent proportions: comparison of eleven methods
inferredcites →https://doi.org/10.1002/14651858.cd000544.pub3openalex-extracted
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis
inferredcites →https://doi.org/10.1007/s00415-018-8813-zopenalex-extracted
Serum anti-JCV antibody indexes in Japanese patients with multiple sclerosis: elevations along with fingolimod treatment duration
inferredcites →https://doi.org/10.1007/s00535-018-1439-1openalex-extracted
Evidence-based clinical practice guidelines for inflammatory bowel disease
inferredcites →https://doi.org/10.1007/s00535-021-01784-1openalex-extracted
Evidence-based clinical practice guidelines for inflammatory bowel disease 2020
inferredcites →https://doi.org/10.1007/s10620-013-2748-0openalex-extracted
Prevalence of Corticosteroids Use and Disease Course After Initial Steroid Exposure in Ulcerative Colitis
inferredcites →https://doi.org/10.1016/j.crohns.2013.03.014openalex-extracted
Oral treatment with a novel small molecule alpha 4 integrin antagonist, AJM300, prevents the development of experimental colitis in mice
inferredcites →https://doi.org/10.1016/j.gtc.2020.08.003openalex-extracted
Assessing Severity of Disease in Patients with Ulcerative Colitis
inferredcites →https://doi.org/10.1016/s1474-4422(17)30282-xopenalex-extracted
Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies
inferredcites →https://doi.org/10.1053/gast.2001.26279openalex-extracted
The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study
inferredcites →https://doi.org/10.1053/j.gastro.2015.08.044openalex-extracted
Safety and Efficacy of AJM300, an Oral Antagonist of α4 Integrin, in Induction Therapy for Patients With Active Ulcerative Colitis
inferredcites →https://doi.org/10.1056/nejm198712243172603openalex-extracted
Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative Colitis
inferredcites →https://doi.org/10.1056/nejmoa020696openalex-extracted
A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
inferredcites →https://doi.org/10.1056/nejmoa1107829openalex-extracted
Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
inferredcites →https://doi.org/10.1080/1744666x.2019.1646127openalex-extracted
Overall and comparative safety of biologic and immunosuppressive therapy in inflammatory bowel diseases
inferredcites →https://doi.org/10.1093/ecco-jcc/jjx009openalex-extracted
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management
inferredcites →https://doi.org/10.1097/mib.0000000000001261openalex-extracted
Safety Considerations with the Use of Corticosteroids and Biologic Therapies in Mild-to-Moderate Ulcerative Colitis
inferredcites →https://doi.org/10.1111/bcp.14151openalex-extracted
AJM300, a novel oral antagonist of α4‐integrin, sustains an increase in circulating lymphocytes: A randomised controlled trial in healthy male subjects
inferredcites →https://doi.org/10.1159/000449077openalex-extracted
Leukocyte Anti-Trafficking Strategies: Current Status and Future Directions
inferredcites →https://doi.org/10.1177/1352458518786075openalex-extracted
Drug-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients
inferredcites →https://doi.org/10.1212/nxi.0000000000000195openalex-extracted
Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values
inferredcites →https://doi.org/10.14309/ajg.0000000000000152openalex-extracted
ACG Clinical Guideline: Ulcerative Colitis in Adults
inferredcites →https://doi.org/10.2146/ajhp140449openalex-extracted
Vedolizumab: An integrin-receptor antagonist for treatment of Crohn’s disease and ulcerative colitis
inferredcites →https://doi.org/10.5217/ir.2020.00026openalex-extracted
Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis
inferredcites →https://doi.org/10.7759/cureus.14764openalex-extracted
Risk of Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis Patient Treated With Natalizumab: A Systematic Review
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.1007/s00011-024-01874-9openalex-snapshot
Consistent efficacy outcomes between phase 2 and phase 3 trials in Crohn’s disease or ulcerative colitis in adults: a meta-analysis
inferred← citeshttps://doi.org/10.1038/s41575-022-00663-1openalex-snapshot
Gut immune cell trafficking: inter-organ communication and immune-mediated inflammation
inferred← citeshttps://doi.org/10.1038/s41575-022-00738-zopenalex-snapshot
Improving IBD outcomes in the era of many treatment options
inferred← citeshttps://doi.org/10.1111/jgh.17000openalex-snapshot
Association of Vascular Cell Adhesion Molecule‐1 Expression in Colonic Mucosa With Mucosal Inflammation and Subsequent Relapse in Patients With Ulcerative Colitis
inferred← citeshttps://doi.org/10.1111/jpc.16519openalex-snapshot
Novel pharmacological developments in the management of paediatric inflammatory bowel disease: Time for guideline update – A narrative review
inferred← citeshttps://doi.org/10.14309/ctg.0000000000000629openalex-snapshot
A Comparison of Treatment Effect Sizes in Matched Phase 2 and Phase 3 Trials of Advanced Therapeutics in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis
inferred← citeshttps://doi.org/10.2169/internalmedicine.5491-25openalex-snapshot
Recent Advances in Molecular Targeted Therapy for Inflammatory Bowel Disease
inferred← citeshttps://doi.org/10.2302/kjm.2022-0015-iropenalex-snapshot
Network Approaches to Uncover Pathogenesis and Therapeutic Targets of Inflammatory Bowel Diseases
inferred← citeshttps://doi.org/10.3862/jcoloproctology.76.580openalex-snapshot
The Forefront of Drug Therapy for Ulcerative Colitis
inferred← citeshttps://doi.org/10.5217/ir.2025.00066openalex-snapshot
Real-world effectiveness and safety of carotegrast methyl in patients with ulcerative colitis: a multicenter retrospective cohort study
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.